PMID- 37199636
OWN - NLM
STAT- MEDLINE
DCOM- 20230825
LR  - 20231119
IS  - 1098-660X (Electronic)
IS  - 0095-1137 (Print)
IS  - 0095-1137 (Linking)
VI  - 61
IP  - 8
DP  - 2023 Aug 23
TI  - State of the Art for Diagnosis of Bacterial Vaginosis.
PG  - e0083722
LID - 10.1128/jcm.00837-22 [doi]
LID - e00837-22
AB  - Bacterial vaginosis (BV) is the most common cause of vaginal discharge among 
      reproductive-age women. It is associated with multiple adverse health outcomes, 
      including increased risk of acquisition of HIV and other sexually transmitted 
      infections (STIs), in addition to adverse birth outcomes. While it is known that 
      BV is a vaginal dysbiosis characterized by a shift in the vaginal microbiota from 
      protective Lactobacillus species to an increase in facultative and strict 
      anaerobic bacteria, its exact etiology remains unknown. The purpose of this 
      minireview is to provide an updated overview of the range of tests currently used 
      for the diagnosis of BV in both clinical and research settings. This article is 
      divided into two primary sections: traditional BV diagnostics and molecular 
      diagnostics. Molecular diagnostic assays, particularly 16S rRNA gene sequencing, 
      shotgun metagenomic sequencing, and fluorescence in situ hybridization (FISH), 
      are specifically highlighted, in addition to multiplex nucleic acid amplification 
      tests (NAATs), given their increasing use in clinical practice (NAATs) and 
      research studies (16S rRNA gene sequencing, shotgun metagenomic sequencing, and 
      FISH) regarding the vaginal microbiota and BV pathogenesis. We also provide a 
      discussion of the strengths and weaknesses of current BV diagnostic tests and 
      discuss future challenges in this field of research.
FAU - Muzny, Christina A
AU  - Muzny CA
AUID- ORCID: 0000-0002-4005-3858
AD  - Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, 
      Alabama, USA.
FAU - Cerca, Nuno
AU  - Cerca N
AUID- ORCID: 0000-0003-3365-3537
AD  - Centre of Biological Engineering, Laboratory of Research in Biofilms Rosario 
      Oliveira, University of Minho, Braga, Portugal.
FAU - Elnaggar, Jacob H
AU  - Elnaggar JH
AD  - Department of Microbiology, Immunology, and Parasitology, Louisiana State 
      University Health Sciences Center, New Orleans, Louisiana, USA.
FAU - Taylor, Christopher M
AU  - Taylor CM
AD  - Department of Microbiology, Immunology, and Parasitology, Louisiana State 
      University Health Sciences Center, New Orleans, Louisiana, USA.
FAU - Sobel, Jack D
AU  - Sobel JD
AUID- ORCID: 0000-0002-5589-4609
AD  - Division of Infectious Diseases, Wayne State University, Detroit, Michigan, USA.
FAU - Van Der Pol, Barbara
AU  - Van Der Pol B
AUID- ORCID: 0000-0003-3064-8564
AD  - Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, 
      Alabama, USA.
LA  - eng
GR  - R01 AI146065/AI/NIAID NIH HHS/United States
GR  - R21 AI167754/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20230518
PL  - United States
TA  - J Clin Microbiol
JT  - Journal of clinical microbiology
JID - 7505564
RN  - 0 (RNA, Ribosomal, 16S)
SB  - IM
MH  - Humans
MH  - Female
MH  - *Vaginosis, Bacterial/diagnosis/microbiology
MH  - RNA, Ribosomal, 16S/genetics
MH  - In Situ Hybridization, Fluorescence
MH  - Vagina/microbiology
MH  - *Sexually Transmitted Diseases
PMC - PMC10446871
OTO - NOTNLM
OT  - bacterial vaginosis
OT  - diagnosis
OT  - molecular diagnostics
OT  - vaginal infection
COIS- The authors declare a conflict of interest. C.A.M. reports receiving grants to 
      her institution from NIAID, Lupin, Abbott Molecular, and Gilead. She also reports 
      honorarium and/or consulting fees from Scynexis, Cepheid, BioNTech, Visby 
      Medical, Elsevier, UpToDate, Abbott Molecular, and Roche. B.V.D.P. reports 
      receiving grants to her institution, honorarium, and/or consulting fees from 
      Abbott Molecular, Becton Dickinson and Company, Binx Health, BioFire, Cepheid, 
      Hologic, Rheonix, Roche, and SpeeDx. The other authors have no conflicts of 
      interest to declare.
EDAT- 2023/05/18 13:09
MHDA- 2023/08/25 06:42
PMCR- 2023/11/18
CRDT- 2023/05/18 10:13
PHST- 2023/08/25 06:42 [medline]
PHST- 2023/05/18 13:09 [pubmed]
PHST- 2023/05/18 10:13 [entrez]
PHST- 2023/11/18 00:00 [pmc-release]
AID - 00837-22 [pii]
AID - jcm.00837-22 [pii]
AID - 10.1128/jcm.00837-22 [doi]
PST - ppublish
SO  - J Clin Microbiol. 2023 Aug 23;61(8):e0083722. doi: 10.1128/jcm.00837-22. Epub 
      2023 May 18.